Oct 31,2017

Senseonics Holdings, Inc. Reports Third Quarter 2017 Financial Results

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the third quarter ended September 30, 2017. Revenue was $2.1 million for the third quarter of 2017, compared to $37,000 for the third quarter of 2016.

View Analyst & Ambassador Comments
Go to original news
Nov 10,2017

Study: Lark's AI coach could help with weight loss, diabetes prevention

A new study reveals that artificial intelligence could be a useful tool to help patients prevent Type 2 diabetes. The study, published in the Journal of Medical Internet Research , showed that patients at risk of Type 2 diabetes who used the Lark Weight Loss Health Coach AI, dropped 2.38 percent of their baseline weight and increase the percentage of healthful meals they ate by 31 percent.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 13,2017

Study: Mobile app could help monitor AMD and diabetic retinopathy

A new study found that a mobile-based app could be an effective way of monitoring age-related mucular degeneration (AMD) and diabetic retinopathy. A study recently presented at the American Academy of Ophthalmology or AAO, reported that patients who used DigiSight's Paxos Checkup app, got comparable results to those who had traditional clinical checkups.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 16,2017

Voluntis gets FDA clearance to add last two basal insulins to app

Medical device software company Voluntis has received an updated FDA clearance (as well as an updated CE mark) for its Insulia app , a "digital companion" app for people with Type 2 diabetes. Insulia offers realtime basal insulin dose coaching, and the new clearance makes the app usable with two additional brands of insulin: Basaglar and Tresiba. The app had already worked for users of Lantus, Levemir, and Toujeo.

REGULATORY FDA

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 22,2017

UK invests in digital diabetes prevention

The National Health Services recently announced that Public Health England and Diabetes is teaming up with tech companies in a pilot program to provide resources for individuals fighting obesity and Type 2 diabetes. About 5,000 patients are expected to participate. The program will have apps, gadgets, wristbands, and innovative digital products provided by Hitachi, Buddi Nujjer, Liva Healthcare, Oviva, and OurPath.

View Analyst & Ambassador Comments
Go to original news
Nov 27,2017

Minimally Invasive CGM company Biolinq raises $10 million in Series A funding

San Diego-based Biolinq, a digital health company specializing in minimally invasive continuous glucose monitoring, raised $10 million in Series A financing. The round was led by M Ventures, in collaboration with Hikma Ventures. Biolinq is currently working on a skin applied, minimally-invasive electrochemical biosensor platform for diabetes patients, which analyzes biomarkers in the interstitial fluid to provide actionable health information. The funding will enable the company to expand its team, and get its product through the clinical validation trials necessary for FDA approval.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Nov 29,2017

New integrations flesh out Verily and Sanofi's Onduo's diabetes management platform

A slew of digital diabetes care companies have announced integrations with the upcoming virtual Type 2 diabetes management platform being developed by Onduo, a joint venture of Verily and Sanofi. These announced services include Voluntis’ Insulia, a digital insulin dose recommendation and coaching system; Glytec’s Glucommander Outpatient, cloud-based software that evaluates blood glucose and patient attribute to adjust insulin dosages; and BioTelemetry’s Telcare cellular-enabled glucometer and cloud-based data system.

COLLABORATION PARTNERSHIP

#product & service

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 30,2017

Analysis shows wearable data could help identify mental health conditions in diabetic populations

A recent data analysis by Evidation Health found that by using wearables, researchers could track activity characteristics associated with co-morbid mental health illness symptoms among people with diabetes. Shefali Kumar, senior associate health outcomes research at Evidation Health said that individuals with mental health illnesses (MHI) are also at a higher risk for developing diabetes than those without. This is because MHI is associated with unhealthy eating habits, less physical activity and a potential increase in weight. The analysis, which was complied by using data from general Achievement use, found that diabetes patients that self-reported symptoms of MHI walk on average 1,469 steps less per day than those without MHI symptoms.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 19,2021

MyDiabetesMyWay selected for the NHS Innovation Accelerator Programme

MyWay Digital Health announced that MyDiabetes My Way is one of the 11 innovations selected to join the nationally celebrated NHS Innovation Accelerator programme (NIA). This is an opportunity and a huge accolade for the company and will make a significant difference in supporting implementation of MyDiabetes My Way across NHS England.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Feb 19,2021

Digital Health Technology Catalyst

MyWay Digital Health and partners have been awarded funding from Innovate UK, for a £1million project to develop an artificial intelligence system to support decision making for clinicians and people with diabetes.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES